drugset / Press release
Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) får markedsføringstilladelse i Europa
2013-01-21 · Novo Nordisk A/S · original novonordisk.com ↗
Degludec
Insulin · regulatory
Insulin degludec/insulin aspart
Insulin degludec/insulin aspart
insulin aspart
insulin degludec
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart · regulatory
insulin degludec/insulin aspart
regular insulin
Bagsværd, den 21. januar 2013 - Novo Nordisk meddelte i dag, at Europa-Kommissionen har givet markedsføringstilladelse til Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) til behandling af diabetes hos voksne. Markedsføringstilladelserne gælder samtlige 27 EU-medlemslande. Yderligere information Medier: Mike Rulis +45 3079 3573 [email protected] Investorer: Kasper Roseeuw Poulsen +45 4442 4303 [email protected] Frank Daniel Mersebach +45 4442 0604 [email protected] Lars Borup Jacobsen +45 3075 3479 [email protected] Selskabsmeddelelse nr. 6 / 2013
The release as fetched from its publisher. novonordisk.com ↗